{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:23:44Z","timestamp":1770413024617,"version":"3.49.0"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1097\/cmr.0b013e32832ccd09","type":"journal-article","created":{"date-parts":[[2010,3,10]],"date-time":"2010-03-10T09:08:26Z","timestamp":1268212106000},"page":"107-117","source":"Crossref","is-referenced-by-count":65,"title":["Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma"],"prefix":"10.1097","volume":"20","author":[{"given":"Helena","family":"P\u00f3pulo","sequence":"first","affiliation":[]},{"given":"Paula","family":"Soares","sequence":"additional","affiliation":[]},{"given":"Ana Sofia","family":"Rocha","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Manuel","family":"Lopes","sequence":"additional","affiliation":[]}],"member":"276","reference":[{"key":"R1-5-20210129","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84\u2009836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"key":"R2-5-20210129","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/0002-9610(80)90204-4","article-title":"Biologic behavior of ocular malignant melanoma and comparison with melanoma of the head and neck","volume":"140","author":"Didolkar","year":"1980","journal-title":"Am J Surg"},{"key":"R3-5-20210129","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF01606450","article-title":"The biology of haematogenous metastasis in human uveal malignant melanoma","volume":"422","author":"McLean","year":"1993","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"R4-5-20210129","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9394(14)77914-0","article-title":"Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology","volume":"96","author":"McLean","year":"1983","journal-title":"Am J Ophthalmol"},{"key":"R5-5-20210129","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/bjo.78.4.252","article-title":"Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases","volume":"78","author":"Paridaens","year":"1994","journal-title":"Br J Ophthalmol"},{"key":"R6-5-20210129","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ophtha.2003.11.001","article-title":"Metastatic pattern and survival in disseminated conjunctival melanoma: implications for sentinel lymph node biopsy","volume":"111","author":"Tuomaala","year":"2004","journal-title":"Ophthalmology"},{"key":"R7-5-20210129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/bjo.86.2.163","article-title":"Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study","volume":"86","author":"Anastassiou","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"R8-5-20210129","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0039-6257(97)00122-7","article-title":"Conjunctival melanoma","volume":"42","author":"Seregard","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"R9-5-20210129","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.pbiomolbio.2006.02.011","article-title":"Adverse effects of ultraviolet radiation: a brief review","volume":"92","author":"Gallagher","year":"2006","journal-title":"Prog Biophys Mol Biol"},{"key":"R10-5-20210129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.survophthal.2004.04.009","article-title":"Sunlight exposure and pathogenesis of uveal melanoma","volume":"49","author":"Singh","year":"2004","journal-title":"Surv Ophthalmol"},{"key":"R11-5-20210129","first-page":"5761","article-title":"Absence of BRAF and NRAS mutations in uveal melanoma","volume":"63","author":"Cruz","year":"2003","journal-title":"Cancer Res"},{"key":"R12-5-20210129","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1167\/iovs.04-0093","article-title":"BRAF mutations in conjunctival melanoma","volume":"45","author":"Gear","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R13-5-20210129","first-page":"5712","article-title":"Lack of BRAF mutations in uveal melanoma","volume":"63","author":"Rimoldi","year":"2003","journal-title":"Cancer Res"},{"key":"R14-5-20210129","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00008390-200412000-00003","article-title":"BRAF mutations are detectable in conjunctival but not uveal melanomas","volume":"14","author":"Spendlove","year":"2004","journal-title":"Melanoma Res"},{"key":"R15-5-20210129","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1167\/iovs.04-1449","article-title":"T1799A BRAF mutations in conjunctival melanocytic lesions","volume":"46","author":"Goldenberg-Cohen","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R16-5-20210129","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1034\/j.1600-0420.1999.770107.x","article-title":"The role of UV-radiation in the development of conjunctival malignant melanoma","volume":"77","author":"El-Shabrawi","year":"1999","journal-title":"Acta Ophthalmol Scand"},{"key":"R17-5-20210129","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.ophtha.2007.06.012","article-title":"Cytogenetics of uveal melanoma: a 7-year clinical experience","volume":"114","author":"Damato","year":"2007","journal-title":"Ophthalmology"},{"key":"R18-5-20210129","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1167\/iovs.04-1460","article-title":"Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients","volume":"46","author":"Kilic","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R19-5-20210129","first-page":"3032","article-title":"Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway","volume":"59","author":"Parrella","year":"1999","journal-title":"Cancer Res"},{"key":"R20-5-20210129","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1442-9071.2004.00917.x","article-title":"Developments in the management of uveal melanoma","volume":"32","author":"Damato","year":"2004","journal-title":"Clin Exp Ophthalmol"},{"key":"R21-5-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"R22-5-20210129","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1471-4892(03)00071-7","article-title":"Targeting mTOR signaling for cancer therapy","volume":"3","author":"Huang","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"R23-5-20210129","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"R24-5-20210129","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1097-2765(02)00636-6","article-title":"Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control","volume":"10","author":"Loewith","year":"2002","journal-title":"Mol Cell"},{"key":"R25-5-20210129","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr Biol"},{"key":"R26-5-20210129","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0092-8674(02)00833-4","article-title":"Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action","volume":"110","author":"Hara","year":"2002","journal-title":"Cell"},{"key":"R27-5-20210129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"key":"R28-5-20210129","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1356-9597.2004.00727.x","article-title":"Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function","volume":"9","author":"Oshiro","year":"2004","journal-title":"Genes Cells"},{"key":"R29-5-20210129","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.molcel.2007.03.003","article-title":"PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase","volume":"25","author":"Sancak","year":"2007","journal-title":"Mol Cell"},{"key":"R30-5-20210129","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/ncb1183","article-title":"Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive","volume":"6","author":"Jacinto","year":"2004","journal-title":"Nat Cell Biol"},{"key":"R31-5-20210129","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"R32-5-20210129","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0960-9822(06)00122-9","article-title":"Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha","volume":"7","author":"Alessi","year":"1997","journal-title":"Curr Biol"},{"key":"R33-5-20210129","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1126\/science.277.5325.567","article-title":"Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B","volume":"277","author":"Stokoe","year":"1997","journal-title":"Science"},{"key":"R34-5-20210129","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1042\/bj3370575","article-title":"Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1","volume":"337","author":"Currie","year":"1999","journal-title":"Biochem J"},{"key":"R35-5-20210129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0092-8674(00)81780-8","article-title":"Negative regulation of PKB\/Akt-dependent cell survival by the tumor suppressor PTEN","volume":"95","author":"Stambolic","year":"1998","journal-title":"Cell"},{"key":"R36-5-20210129","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ceb.2005.02.010","article-title":"Recent advances in the protein kinase B signaling pathway","volume":"17","author":"Woodgett","year":"2005","journal-title":"Curr Opin Cell Biol"},{"key":"R37-5-20210129","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1002\/j.1460-2075.1996.tb01045.x","article-title":"Mechanism of activation of protein kinase B by insulin and IGF-1","volume":"15","author":"Alessi","year":"1996","journal-title":"EMBO J"},{"key":"R38-5-20210129","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat Cell Biol"},{"key":"R39-5-20210129","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1101\/gad.1110003","article-title":"Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling","volume":"17","author":"Inoki","year":"2003","journal-title":"Genes Dev"},{"key":"R40-5-20210129","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0960-9822(03)00506-2","article-title":"Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb","volume":"13","author":"Tee","year":"2003","journal-title":"Curr Biol"},{"key":"R41-5-20210129","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.cub.2005.02.053","article-title":"Rheb binds and regulates the mTOR kinase","volume":"15","author":"Long","year":"2005","journal-title":"Curr Biol"},{"key":"R42-5-20210129","doi-asserted-by":"crossref","first-page":"10189","DOI":"10.1074\/jbc.M210837200","article-title":"Identification of a proline-rich Akt substrate as a 14-3-3 binding partner","volume":"278","author":"Kovacina","year":"2003","journal-title":"J Biol Chem"},{"key":"R43-5-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1083\/jcb.200403069","article-title":"The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins","volume":"166","author":"Harrington","year":"2004","journal-title":"J Cell Biol"},{"key":"R44-5-20210129","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1128\/MCB.01254-05","article-title":"Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis","volume":"26","author":"Shah","year":"2006","journal-title":"Mol Cell Biol"},{"key":"R45-5-20210129","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J Clin Invest"},{"key":"R46-5-20210129","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1128\/MCB.00289-08","article-title":"The TSC1-TSC2 complex is required for proper activation of mTOR complex 2","volume":"28","author":"Huang","year":"2008","journal-title":"Mol Cell Biol"},{"key":"R47-5-20210129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semcdb.2004.11.005","article-title":"mTOR, translational control and human disease","volume":"16","author":"Tee","year":"2005","journal-title":"Semin Cell Dev Biol"},{"key":"R48-5-20210129","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.4161\/cbt.5.9.3175","article-title":"Therapeutic targets: MTOR and related pathways","volume":"5","author":"Dancey","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"R49-5-20210129","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2006.06.0442","article-title":"Toward a molecular classification of melanoma","volume":"25","author":"Fecher","year":"2007","journal-title":"J Clin Oncol"},{"key":"R50-5-20210129","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","article-title":"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR","volume":"98","author":"Neshat","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R51-5-20210129","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature06913","article-title":"The cancer biomarker problem","volume":"452","author":"Sawyers","year":"2008","journal-title":"Nature"},{"key":"R52-5-20210129","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/erc.0.0080249","article-title":"mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer","volume":"8","author":"Yu","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"R53-5-20210129","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"R54-5-20210129","first-page":"4916","article-title":"A novel N-ras mutation in malignant melanoma is associated with excellent prognosis","volume":"61","author":"Demunter","year":"2001","journal-title":"Cancer Res"},{"key":"R55-5-20210129","first-page":"2881","article-title":"Loss of PTEN promotes tumor development in malignant melanoma","volume":"63","author":"Stahl","year":"2003","journal-title":"Cancer Res"},{"key":"R56-5-20210129","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1038\/sj.bjc.6604637","article-title":"A novel AKT3 mutation in melanoma tumours and cell lines","volume":"99","author":"Davies","year":"2008","journal-title":"Br J Cancer"},{"key":"R57-5-20210129","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10555-005-1577-9","article-title":"Functional and therapeutic significance of Akt deregulation in malignant melanoma","volume":"24","author":"Robertson","year":"2005","journal-title":"Cancer Metastasis Rev"},{"key":"R58-5-20210129","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1158\/0008-5472.CAN-04-1399","article-title":"Deregulated Akt3 activity promotes development of malignant melanoma","volume":"64","author":"Stahl","year":"2004","journal-title":"Cancer Res"},{"key":"R59-5-20210129","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/sj.jid.5701074","article-title":"mTOR is activated in the majority of malignant melanomas","volume":"128","author":"Karbowniczek","year":"2008","journal-title":"J Invest Dermatol"},{"key":"R60-5-20210129","first-page":"547","article-title":"Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines","volume":"19","author":"Bundscherer","year":"2008","journal-title":"Oncol Rep"},{"key":"R61-5-20210129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1479-5876-3-39","article-title":"Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin","volume":"3","author":"Molhoek","year":"2005","journal-title":"J Transl Med"},{"key":"R62-5-20210129","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1200\/JCO.2005.02.2418","article-title":"High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma","volume":"24","author":"Abdel-Rahman","year":"2006","journal-title":"J Clin Oncol"},{"key":"R63-5-20210129","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00008390-200508000-00003","article-title":"Immunohistochemical expression of phospho-Akt in uveal melanoma","volume":"15","author":"Saraiva","year":"2005","journal-title":"Melanoma Res"},{"key":"R64-5-20210129","article-title":"AJCC cancer staging manual. 6th ed","author":"Greene","year":"2002"},{"key":"R65-5-20210129","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000071207","article-title":"Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas","volume":"65","author":"Cruz","year":"2003","journal-title":"Oncology"},{"key":"R66-5-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1096-9896(199805)185:1<71::AID-PATH42>3.0.CO;2-S","article-title":"Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?","volume":"185","author":"Soares","year":"1998","journal-title":"J Pathol"},{"key":"R67-5-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1210\/jc.2005-1336","article-title":"PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma","volume":"91","author":"Castro","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"R68-5-20210129","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"key":"R69-5-20210129","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1309\/YT58WWMTA6YR1PRV","article-title":"Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome","volume":"124","author":"Slipicevic","year":"2005","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"R70-5-20210129","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70162-8","article-title":"Pigmented lesions of the conjunctiva","volume":"38","author":"Farber","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"R71-5-20210129","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/01.LAB.0000101732.89463.29","article-title":"Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea","volume":"83","author":"Weber","year":"2003","journal-title":"Lab Invest"},{"key":"R72-5-20210129","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/sj.bjc.6602598","article-title":"Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS","volume":"92","author":"Zuidervaart","year":"2005","journal-title":"Br J Cancer"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0b013e32832ccd09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T20:23:24Z","timestamp":1621887804000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008390-201004000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0b013e32832ccd09","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}